Follicum announced on September 17, 2019 that the company had received a Notice of Allowance from the US Patent and Trademark Office regarding the patent application “Novel Compositions and Uses Thereof”. The patent has now formally been granted by the USPTO.
The patent is valid until 2032.
In this patent family, Follicum already has two granted US patents covering different aspects of FOL-005. Follicum has subsequently submitted a follow-up, so called Continuing Patent Application, which extends and broadens the protection around the therapeutic use of FOL-005. Follicum has now received a formal grant for this follow up application. The patent provides protection in the United States until the year 2032. The USPTO will publish the granted patent on December 31, 2019.
“The United States is one of the largest markets for Follicum, and hence this patent is of major importance to us and an important step in our global patent strategy. We are continuously working to strategically expand our patent portfolio in our key markets,” says CEO Jan Alenfall.
FOL-005 is a modified, short version of the endogenous protein, osteopontin. In two completed clinical studies, treatment with FOL-005 has been shown to be effective and safe. The first study was done in healthy volunteers while the other one was conducted in alopecia patients, i.e. in men with incipient baldness. In both studies, patients were treated at the clinic with intradermal injections, 2 or 3 times a week. Planning for a phase II study is currently underway aiming at investigating the hair-stimulating effect of daily treatment with different doses of the new topical formulation.